Hydroxyurea Therapy Does Not Impact Current Survival Estimates in the East London Sickle Cell Newborn Cohort Study

Conclusions: The study is the first to evaluate survival in a newborn cohort past the age of 20 years. We have confirmed a low mortality rate in childhood, but increased number of deaths in young adults including those with HbSC. This study provides evidence of the benefit of newborn screening and comprehensive care which is accessible at all ages, free of charge. The uptake of HU, particularly at a young age, has been low and a positive effect of HU on survival as described in other studies has not yet been observed in this cohort. Earlier initiation of disease-modifying treatment and longer-term follow-up will be required to provide evidence of treatment effects of HU and other therapies on survival.Figure.DisclosuresTelfer: Bluebird Bio: Honoraria, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; ApoPharma Inc.: Membership on an entity's Board of Directors or advisory committees; Terumo: Honoraria. Kaya: Novartis: Honoraria; Novartis: Consultancy; AstraZeneca: Consultancy; British Society For Haematology: Membership on an entity's Board of Directors or advisory committees.
Source: Blood - Category: Hematology Authors: Tags: 114. Hemoglobinopathies, Excluding Thalassemia-Clinical: Poster III Source Type: research